Mabion Launches €500K Oncology Contest to Boost Recombinant Cancer Therapies

• Mabion has launched a €500,000 oncology contest to support biotech innovators in developing recombinant protein-based cancer therapies.

• The winner will be announced at CPHI Frankfurt 2025 and receive access to Mabion’s integrated CDMO services.

Mabion, a biotech-focused CDMO, has launched a €500,000 contest aimed at accelerating the development of recombinant protein-based oncology treatments. The initiative was unveiled at BIO International Convention 2025 and will conclude at CPHI Worldwide in Frankfurt this October.

The contest offers biotech innovators a chance to secure CDMO support for early-stage oncology programs. Selected participants will undergo a structured proposal process, including NDA execution and collaboration with Mabion’s business development team. The winner will receive a €500,000 credit for integrated contract manufacturing services such as process development, upstream/downstream production, and clinical supply.

The initiative is part of Mabion’s broader effort to bridge the funding gap many oncology projects face. “This contest is our invitation to innovators who just need the right partner. We’re offering more than a prize; we’re offering a path to impact,” said Julita Balcerek, Ph.D., COO at Mabion.

A panel of experts from academia and industry will evaluate submissions based on scientific merit, feasibility, and patient impact. In addition to the grand prize, runner-up projects may be invited into further partnership discussions.

The campaign is supported by digital engagement and on-site activations at BIO and CPHI events, reinforcing Mabion’s strategic focus on fostering long-term collaborations in oncology drug development.